UBS downgrades Banco Bilbao stock rating on valuation concerns

UBS downgraded BBVA to Neutral from Buy and cut its price target to €20.50 from €22.30, implying roughly 5% upside from current levels. The bank’s record FY2025 net attributable profit of €10.5 billion and 4.5% growth were overshadowed by UBS’s concerns about limited EPS upgrade potential, valuation, and weaker disinflation in Turkey. Barclays also turned more cautious, downgrading BBVA to Equalweight and lowering its target to €20.50.

Analysis

The key market message is not the downgrade itself, but the convergence of independent valuation warnings from multiple desks into a single narrative: BBVA’s earnings quality is good, but the market is increasingly paying a full multiple for a bank whose next leg of upside depends on factors it does not control. When a bank’s rerating has already happened, further upside usually requires either a second derivative of earnings revisions or a lower equity risk premium; neither is obvious here. That makes the stock vulnerable to any disappointment in rate normalization, FX translation, or emerging-market sentiment over the next 1-2 quarters.

The more interesting second-order effect is relative positioning inside Spanish banks. If BBVA’s multiple is now anchored near sector average, the stock stops being the obvious valuation arbitrage and becomes a crowded quality compounder with less room to outperform on benign headlines. That creates a cleaner relative-value setup in favor of names with more domestic beta and less emerging-market carry risk, especially if investors rotate toward banks where earnings are more levered to European rate cuts and less exposed to Turkey/Mexico-style macro noise.

The consensus may be underestimating how quickly valuation compression can happen once guidance momentum stalls. BBVA’s record profits are backward-looking; the market will care more about whether incremental buybacks/dividends can offset a de-rating in the earnings multiple. If FX turns adverse or emerging-market rates soften, the next move in the stock could come from multiple contraction rather than profit disappointment, which typically plays out over weeks to months rather than years.

Contrarianly, this is not a broken fundamental story—just one where expectations have outrun self-help. That means the right way to express caution is not a blind short, but a relative-value or options-based expression that isolates valuation risk while limiting exposure to broad bank-sector strength. If Spanish banks rerate higher on macro tailwinds, BBVA may still participate; the question is whether it can outperform from here, and the answer looks materially less compelling.

Key Decisions for Investors

• Reduce BBVA to market weight vs. SAN over the next 1-2 weeks; prefer SAN as the cleaner Spain exposure with less emerging-market valuation overhang. Risk/reward: BBVA downside comes from multiple compression, while SAN has more room for a catch-up rerating if the sector stays bid.
• Pair trade: short BBVA / long a basket of domestic European banks or SAN into the next 4-8 weeks. The trade monetizes the gap between a fully valued emerging-market-linked bank and a more domestically anchored peer set; stop if BBVA regains relative strength on a clear EPS revision cycle.
• For directional exposure, use BBVA put spreads 2-3 months out rather than stock shorting. This captures the most likely catalyst window for valuation de-rating while limiting carry cost if the market remains constructive on banks.
• Watch for a reversal trigger in Turkey/FX and EM rates over the next quarter; if these stabilize and BBVA re-accelerates guidance, cover relative shorts quickly. This is a thesis on missing upside, not structural impairment.